Combined Rosiglitazone and Forskolin Have Neuroprotective Effects in SD Rats after Spinal Cord Injury
PPAR Research · 21.06.2018 · 2018 · 1-11
DOI: 10.1155/2018/3897478 ↗Kurz gefasst
Fachartikel in der Zeitschrift PPAR Research, erschienen am 21.06.2018. Verfasst von Qing-Qi Meng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Guangzhou Red Cross Hospital, Jinan University, 396 Tongfu Road, Guangzhou 510120, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangzhou Science Foundation, Guangzhou Health Science and Technology Project.
Abstract (Originalsprache)
The peroxisome proliferator-activated receptor gamma (PPAR- γ ) agonist rosiglitazone inhibits NF- κ B expression and endogenous neural stem cell differentiation into neurons and reduces the inflammatory cascade after spinal cord injury (SCI). The aim of this study was to explore the mechanisms underlying rosiglitazone-mediated neuroprotective effects and regulation of the balance between the inflammatory cascade and generation of endogenous spinal cord neurons by using a spinal cord-derived neural stem cell culture system as well as SD rat SCI model. Activation of PPAR- γ could promote neural stem cell proliferation and inhibit PKA expression and neuronal formation in vitro. In the SD rat SCI model, the rosiglitazone + forskolin group showed better locomotor recovery compared to the rosiglitazone and forskolin groups. MAP2 expression was higher in the rosiglitazone + forskolin group than in the rosiglitazone group, NF- κ B expression was lower in the rosiglitazone + forskolin group than in the forskolin group, and NeuN expression was higher in the rosiglitazone + forskolin group than in the forskolin group. PPAR- γ activation likely inhibits NF- κ B, thereby reducing the inflammatory cascade, and PKA activation likely promotes neuronal cell regeneration.
Autor:innen und Institutionen
- Department of Orthopedics, Guangzhou Red Cross Hospital, Jinan University, 396 Tongfu Road, Guangzhou 510120, China.
- Laboratory Research Center, Guangdong Medical University, Zhanjiang 524001, China.
- Department of Gastroenterology, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou 51000, China.
ORCID-Profile: Qing-Qi Meng, Wei Lei, Siming Li
Förderung
- National Natural Science Foundation of China
- Guangzhou Science Foundation
- Guangzhou Health Science and Technology Project
Zitieren
APA
Meng, Q. Q., Lei, W., Chen, H., Feng, Z. C., Hu, L. Q., Zhang, X. L., & Li, S. (2018). Combined Rosiglitazone and Forskolin Have Neuroprotective Effects in SD Rats after Spinal Cord Injury. PPAR Research, 2018, 1-11. https://doi.org/10.1155/2018/3897478
Vancouver
Meng QQ, Lei W, Chen H, Feng ZC, Hu LQ, Zhang XL, et al. Combined Rosiglitazone and Forskolin Have Neuroprotective Effects in SD Rats after Spinal Cord Injury. PPAR Research. 2018;2018:1-11. doi:10.1155/2018/3897478
BibTeX
@article{Meng2018,
author = {Meng, Qing-Qi and Lei, Wei and Chen, Hao and Feng, Zhen-Cheng and Hu, Li-Qiong and Zhang, Xing-Liang and Li, Siming},
title = {Combined Rosiglitazone and Forskolin Have Neuroprotective Effects in SD Rats after Spinal Cord Injury},
journal = {PPAR Research},
year = {2018},
volume = {2018},
pages = {1--11},
doi = {10.1155/2018/3897478}
}
EUVIMED